Nicholas Investment Partners LP cut its position in bluebird bio Inc (NASDAQ:BLUE) by 20.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,662 shares of the biotechnology company’s stock after selling 14,667 shares during the quarter. bluebird bio comprises about 0.7% of Nicholas Investment Partners LP’s holdings, making the stock its 25th largest position. Nicholas Investment Partners LP owned about 0.12% of bluebird bio worth $10,092,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of BLUE. Meeder Asset Management Inc. raised its stake in shares of bluebird bio by 2,110.3% in the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 612 shares during the period. NuWave Investment Management LLC bought a new stake in shares of bluebird bio during the 4th quarter valued at $135,000. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares during the period. Biondo Investment Advisors LLC bought a new stake in shares of bluebird bio during the 3rd quarter valued at $203,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of bluebird bio during the 2nd quarter valued at $211,000.
A number of analysts recently issued reports on BLUE shares. Cantor Fitzgerald decreased their price objective on bluebird bio from $122.00 to $113.00 and set an “underweight” rating on the stock in a research note on Thursday, February 22nd. William Blair started coverage on bluebird bio in a research note on Monday, March 5th. They set an “outperform” rating and a $242.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $152.00 price objective (up from $151.00) on shares of bluebird bio in a research note on Monday, February 26th. Barclays reiterated an “overweight” rating and set a $209.00 price objective (up from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th. Finally, Jefferies Group upgraded bluebird bio from a “hold” rating to a “buy” rating and boosted their price objective for the company from $130.00 to $211.00 in a research note on Monday, December 11th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $192.35.
In other news, COO Susanna Gatti High sold 17,262 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total value of $3,381,798.42. Following the completion of the transaction, the chief operating officer now directly owns 28,512 shares in the company, valued at approximately $5,585,785.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Davidson sold 3,522 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $173.61, for a total value of $611,454.42. Following the completion of the transaction, the insider now owns 13,959 shares of the company’s stock, valued at $2,423,421.99. The disclosure for this sale can be found here. Insiders sold a total of 64,598 shares of company stock valued at $12,370,309 over the last quarter. Company insiders own 3.90% of the company’s stock.
bluebird bio Inc (NASDAQ:BLUE) traded down $3.15 during trading on Wednesday, reaching $220.20. The company had a trading volume of 594,308 shares, compared to its average volume of 696,843. bluebird bio Inc has a twelve month low of $74.45 and a twelve month high of $236.17. The stock has a market capitalization of $11,010.00, a PE ratio of -40.93 and a beta of 2.05.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The business had revenue of $4.17 million for the quarter, compared to analysts’ expectations of $7.11 million. During the same quarter in the previous year, the firm earned ($1.88) earnings per share. bluebird bio’s quarterly revenue was up 169.0% compared to the same quarter last year. equities analysts anticipate that bluebird bio Inc will post -8.25 EPS for the current fiscal year.
WARNING: This report was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://ledgergazette.com/2018/03/14/bluebird-bio-inc-blue-shares-sold-by-nicholas-investment-partners-lp.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.